BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18458136)

  • 1. In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
    Ruan SY; Chu CC; Hsueh PR
    Antimicrob Agents Chemother; 2008 Aug; 52(8):2919-22. PubMed ID: 18458136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.
    Mario DA; Denardi LB; Bandeira LA; Antunes MS; Santurio JM; Severo LC; Alves SH
    Mem Inst Oswaldo Cruz; 2012 May; 107(3):433-6. PubMed ID: 22510843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
    Dagi HT; Findik D; Senkeles C; Arslan U
    Ann Clin Microbiol Antimicrob; 2016 May; 15(1):36. PubMed ID: 27245756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing epidemiology of candidaemia in Australia.
    Chapman B; Slavin M; Marriott D; Halliday C; Kidd S; Arthur I; Bak N; Heath CH; Kennedy K; Morrissey CO; Sorrell TC; van Hal S; Keighley C; Goeman E; Underwood N; Hajkowicz K; Hofmeyr A; Leung M; Macesic N; Botes J; Blyth C; Cooley L; George CR; Kalukottege P; Kesson A; McMullan B; Baird R; Robson J; Korman TM; Pendle S; Weeks K; Liu E; Cheong E; Chen S;
    J Antimicrob Chemother; 2017 Apr; 72(4):1103-1108. PubMed ID: 28364558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and Antifungal Susceptibility of the Emerging Fungal Species,
    Sikora M; Kuthan R; Piskorska-Malolepsza K; Golas-Pradzynska M; Domański D; Augustynowicz-Kopeć E; Swoboda-Kopec E
    Pol J Microbiol; 2019 Sep; 68(3):303-308. PubMed ID: 31880875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.
    Spreghini E; Orlando F; Sanguinetti M; Posteraro B; Giannini D; Manso E; Barchiesi F
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1215-22. PubMed ID: 22203604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.
    Pfaller MA; Castanheira M; Lockhart SR; Ahlquist AM; Messer SA; Jones RN
    J Clin Microbiol; 2012 Apr; 50(4):1199-203. PubMed ID: 22278842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods.
    Kiraz N; Dag I; Yamac M; Kiremitci A; Kasifoglu N; Oz Y
    Antimicrob Agents Chemother; 2010 May; 54(5):2244-7. PubMed ID: 20194697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
    González GM; Elizondo M; Ayala J
    J Clin Microbiol; 2008 Sep; 46(9):2902-5. PubMed ID: 18632907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.
    Nagappan V; Boikov D; Vazquez JA
    Antimicrob Agents Chemother; 2010 Jan; 54(1):522-5. PubMed ID: 19841143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro fungicidal activities of anidulafungin, caspofungin, and micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis evaluated by time-kill studies.
    Gil-Alonso S; Jauregizar N; Cantón E; Eraso E; Quindós G
    Antimicrob Agents Chemother; 2015; 59(6):3615-8. PubMed ID: 25801575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
    Chen TC; Chen YH; Chen YC; Lu PL
    Kaohsiung J Med Sci; 2012 Jun; 28(6):306-15. PubMed ID: 22632885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.
    Chaturvedi V; Ramani R; Andes D; Diekema DJ; Pfaller MA; Ghannoum MA; Knapp C; Lockhart SR; Ostrosky-Zeichner L; Walsh TJ; Marchillo K; Messer S; Welshenbaugh AR; Bastulli C; Iqbal N; Paetznick VL; Rodriguez J; Sein T
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1543-8. PubMed ID: 21282457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients.
    Burn AK; Fothergill AW; Kirkpatrick WR; Coco BJ; Patterson TF; McCarthy DI; Rinaldi MG; Redding SW
    J Clin Microbiol; 2004 Dec; 42(12):5846-8. PubMed ID: 15583322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species.
    Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
    J Infect Chemother; 2009 Feb; 15(1):1-5. PubMed ID: 19280292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ng KP; Colombo A; Finquelievich J; Barnes R; Wadula J;
    J Clin Microbiol; 2008 Mar; 46(3):842-9. PubMed ID: 18199791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal susceptibility of Candida isolates at one institution.
    Katsuragi S; Sata M; Kobayashi Y; Miyoshi T; Yamashita Y; Neki R; Horiuchi C; Yamanaka K; Kamiya C; Iwanaga N; Tanaka H; Ikeda T; Yoshimatsu J
    Med Mycol J; 2014; 55(1):E1-7. PubMed ID: 24682093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
    Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
    BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal susceptibility of bloodstream Candida isolates in Sfax hospital: Tunisia.
    Sellami A; Sellami H; Néji S; Makni F; Abbes S; Cheikhrouhou F; Chelly H; Bouaziz M; Hammami B; Ben Jemaa M; Khaled S; Ayadi A
    Mycopathologia; 2011 Jun; 171(6):417-22. PubMed ID: 21170738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.